Andy Geall News Today

Precision NanoSystems (PNI) will enter into a licensing agreement with Replicate Bioscience to develop self-replicating RNA (srRNA) therapies.

How COVID Unlocked the Power of RNA Vaccines News Highlights: How COVID Unlocked the Power of RNA Vaccines It was a Friday afternoon in March 2013 when Andy Geall got the call. Three people in China had just become infected with a new form of bird flu. The global head of vaccine research at Novartis, Rino Rappuoli, wanted to know if Geall and his colleagues were ready to put their new vaccine technology to the test. A year earlier, Geall’s team at the Novartis US Research Center in Cambridg...